CNS Pharmaceuticals is a preclinical pharmaceutical company. Co. focuses on the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. Co.'s product under development is Berubicin, a development stage anthracycline to treat glioblastoma. Berubicin is an anthracycline, a class of drugs that are among the chemotherapy drugs known. Berubicin intercalates into deoxyribonucleic acid (DNA) and interrupts topoisomerase II activity, resulting in the inhibition of DNA replication and repair, and RNA and protein synthesis. The CNSP stock yearly return is shown above.
The yearly return on the CNSP stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CNSP annual return calculation with any dividends reinvested as applicable (on ex-dates).
|